Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
27.07
-0.03 (-0.11%)
At close: Feb 21, 2025, 4:00 PM
27.08
+0.01 (0.04%)
After-hours: Feb 21, 2025, 5:59 PM EST
Edgewise Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Edgewise Therapeutics stock have an average target of 42.71, with a low estimate of 30 and a high estimate of 51. The average target predicts an increase of 57.78% from the current stock price of 27.07.
Analyst Consensus: Buy
* Price targets were last updated on Jan 22, 2025.
Analyst Ratings
The average analyst rating for Edgewise Therapeutics stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Hold Initiates $30 | Hold | Initiates | $30 | +10.82% | Jan 22, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $45 → $50 | Buy | Maintains | $45 → $50 | +84.71% | Dec 17, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $33 → $50 | Strong Buy | Maintains | $33 → $50 | +84.71% | Nov 27, 2024 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $45 | Buy | Initiates | $45 | +66.24% | Nov 22, 2024 |
| Wedbush | Wedbush | Buy Maintains $44 → $45 | Buy | Maintains | $44 → $45 | +66.24% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.52
from -1.57
EPS Next Year
-1.91
from -1.52
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 33.6M | |||
| Avg | n/a | n/a | 7.3M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.46 | -1.59 | -1.89 | |||
| Avg | -1.52 | -1.91 | -2.20 | |||
| Low | -1.60 | -2.23 | -2.84 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.